Title:
CDK2 INHIBITORS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/116884
Kind Code:
A1
Abstract:
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt, or a stereoisomer thereof and their use in, e.g. treating a disease or disorder associated with CDK2. This disclosure also features compositions containing the same as well as methods of using and making the same.
More Like This:
Inventors:
ZHAO FENG (CN)
LI HAILONG (CN)
HE HU (CN)
ZHONG WENGE (CN)
WANG YUANHAO (CN)
CHEN XIUMEI (CN)
HUANG WEI (CN)
SUN XIANQIANG (CN)
YU YANG (CN)
HUANG JUNHONG (CN)
LIU WEI (CN)
CHEN XINDE (CN)
LI HAILONG (CN)
HE HU (CN)
ZHONG WENGE (CN)
WANG YUANHAO (CN)
CHEN XIUMEI (CN)
HUANG WEI (CN)
SUN XIANQIANG (CN)
YU YANG (CN)
HUANG JUNHONG (CN)
LIU WEI (CN)
CHEN XINDE (CN)
Application Number:
PCT/CN2022/141421
Publication Date:
June 29, 2023
Filing Date:
December 23, 2022
Export Citation:
Assignee:
QILU REGOR THERAPEUTICS INC (CN)
ZHAO FENG (CN)
ZHAO FENG (CN)
International Classes:
A61K31/415; A61P35/00; A61K31/4155; A61K31/4365; A61K31/437; A61K31/4439; A61K31/454; A61K31/4545; A61K31/497; A61K31/4985; A61K31/506; A61K31/519; A61K31/5377; C07D231/38; C07D401/12; C07D401/14; C07D403/12; C07D405/12; C07D405/14; C07D417/12; C07D471/04; C07D487/04; C07D491/048; C07D495/04
Domestic Patent References:
| WO2020157652A2 | 2020-08-06 | |||
| WO2021254384A1 | 2021-12-23 | |||
| WO2021236650A1 | 2021-11-25 | |||
| WO2021170076A1 | 2021-09-02 | |||
| WO2021072232A1 | 2021-04-15 | |||
| WO2020223469A1 | 2020-11-05 | |||
| WO2006056399A2 | 2006-06-01 | |||
| WO2004005281A1 | 2004-01-15 | |||
| WO2003037347A1 | 2003-05-08 | |||
| WO2003099771A2 | 2003-12-04 | |||
| WO2004046120A2 | 2004-06-03 | |||
| WO2000009495A1 | 2000-02-24 | |||
| WO2005028444A1 | 2005-03-31 | |||
| WO2004080980A1 | 2004-09-23 | |||
| WO2004056786A2 | 2004-07-08 | |||
| WO2003024967A2 | 2003-03-27 | |||
| WO2001064655A1 | 2001-09-07 | |||
| WO2000053595A1 | 2000-09-14 | |||
| WO2001014402A1 | 2001-03-01 | |||
| WO2009085185A1 | 2009-07-09 | |||
| WO2012129344A1 | 2012-09-27 | |||
| WO2011101409A1 | 2011-08-25 | |||
| WO2003062236A1 | 2003-07-31 | |||
| WO2010075074A1 | 2010-07-01 | |||
| WO2012061156A1 | 2012-05-10 |
Foreign References:
| US5521184A | 1996-05-28 | |||
| USPP60578491P |
Other References:
CHOHAN TAHIR ET AL: "Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents", CURRENT MEDICINAL CHEMISTRY, vol. 22, no. 2, 8 December 2014 (2014-12-08), NL, pages 237 - 263, XP055916728, ISSN: 0929-8673, DOI: 10.2174/0929867321666141106113633
JANSA JOSEF ET AL: "Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 216, 1 April 2021 (2021-04-01), AMSTERDAM, NL, pages 113309, XP055916729, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113309
HASSAN GHANEYA S ET AL: "Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 218, 18 March 2021 (2021-03-18), XP086560165, ISSN: 0223-5234, [retrieved on 20210318], DOI: 10.1016/J.EJMECH.2021.113389
ABDEL-RAHMAN ADEL A.-H. ET AL: "Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity", vol. 26, no. 13, 26 June 2021 (2021-06-26), DE, pages 3923, XP055916730, ISSN: 1433-1373, Retrieved from the Internet DOI: 10.3390/molecules26133923
HENLEY, S. A.F. A. DICK, CELL DIV, vol. 7, no. 1, 2012, pages 10
EKHOLM, S. V.S. I. REED, CURR OPIN CELL BIOL, vol. 12, no. 6, 2000, pages 676 - 84
XU, X. ET AL., BIOCHEMISTRY, vol. 38, no. 27, 1999, pages 8713 - 22
KEYOMARSI, K. ET AL., N ENGL J MED, vol. 347, no. 20, 2002, pages 1566 - 75
NAKAYAMA, N. ET AL., CANCER, vol. 116, no. 11, 2010, pages 2621 - 34
AU-YEUNG, G. ET AL., CLIN CANCER RES, vol. 23, no. 7, 2017, pages 1862 - 1874
ROSEN, D. G. ET AL., CANCER, vol. 106, no. 9, 2006, pages 1925 - 32
SCALTRITI, M. ET AL., PROC NATL ACAD SCI USA, vol. 108, no. 9, 2011, pages 3761 - 6
HERRERA-ABREU, M. T. ET AL., CANCER RES, vol. 76, no. 8, 2016, pages 2301 - 13
CHEN, Y N. ET AL., PROC NATL ACAD SCI USA, vol. 96, no. 8, 1999, pages 4325 - 9
MENDOZA, N. ET AL., CANCER RES, vol. 63, no. 5, 2003, pages 1020 - 4
CICENAS, J. ET AL., CANCERS (BASEL, vol. 6, no. 4, 2014, pages 2224 - 42
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SMITH, ROGER M.: "Chromatographic Science Series", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, article "Supercritical Fluid Chromatography with Packed Columns", pages: 223 - 249
FINNINMORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
THOMAS SORRELL: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
MOLENAAR ET AL., PROC NATL ACAD SCI USA, vol. 106, no. 31, pages 12968 - 12973
HU, S. ET AL., MOL CANCER THER, vol. 14, no. 11, 2015, pages 2576 - 85
TAKADA ET AL., CANCER RES, vol. 77, no. 18, 2017, pages 4881 - 4893
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1996, MEDICAL ECONOMICS COMPANY
MORRISONBOYD: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", vol. I-XII, 1991, JOHN WILEY AND SONS
JANSA JOSEF ET AL: "Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 216, 1 April 2021 (2021-04-01), AMSTERDAM, NL, pages 113309, XP055916729, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113309
HASSAN GHANEYA S ET AL: "Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 218, 18 March 2021 (2021-03-18), XP086560165, ISSN: 0223-5234, [retrieved on 20210318], DOI: 10.1016/J.EJMECH.2021.113389
ABDEL-RAHMAN ADEL A.-H. ET AL: "Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity", vol. 26, no. 13, 26 June 2021 (2021-06-26), DE, pages 3923, XP055916730, ISSN: 1433-1373, Retrieved from the Internet
HENLEY, S. A.F. A. DICK, CELL DIV, vol. 7, no. 1, 2012, pages 10
EKHOLM, S. V.S. I. REED, CURR OPIN CELL BIOL, vol. 12, no. 6, 2000, pages 676 - 84
XU, X. ET AL., BIOCHEMISTRY, vol. 38, no. 27, 1999, pages 8713 - 22
KEYOMARSI, K. ET AL., N ENGL J MED, vol. 347, no. 20, 2002, pages 1566 - 75
NAKAYAMA, N. ET AL., CANCER, vol. 116, no. 11, 2010, pages 2621 - 34
AU-YEUNG, G. ET AL., CLIN CANCER RES, vol. 23, no. 7, 2017, pages 1862 - 1874
ROSEN, D. G. ET AL., CANCER, vol. 106, no. 9, 2006, pages 1925 - 32
SCALTRITI, M. ET AL., PROC NATL ACAD SCI USA, vol. 108, no. 9, 2011, pages 3761 - 6
HERRERA-ABREU, M. T. ET AL., CANCER RES, vol. 76, no. 8, 2016, pages 2301 - 13
CHEN, Y N. ET AL., PROC NATL ACAD SCI USA, vol. 96, no. 8, 1999, pages 4325 - 9
MENDOZA, N. ET AL., CANCER RES, vol. 63, no. 5, 2003, pages 1020 - 4
CICENAS, J. ET AL., CANCERS (BASEL, vol. 6, no. 4, 2014, pages 2224 - 42
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SMITH, ROGER M.: "Chromatographic Science Series", vol. 75, 1998, LOUGHBOROUGH UNIVERSITY, article "Supercritical Fluid Chromatography with Packed Columns", pages: 223 - 249
FINNINMORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
THOMAS SORRELL: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
MOLENAAR ET AL., PROC NATL ACAD SCI USA, vol. 106, no. 31, pages 12968 - 12973
HU, S. ET AL., MOL CANCER THER, vol. 14, no. 11, 2015, pages 2576 - 85
TAKADA ET AL., CANCER RES, vol. 77, no. 18, 2017, pages 4881 - 4893
GOODMANGILMAN: "The Pharmacological Basis of Therapeutics", 1996, MEDICAL ECONOMICS COMPANY
MORRISONBOYD: "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", vol. I-XII, 1991, JOHN WILEY AND SONS
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: